Profile

Arthur W. Blackstock Jr, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

54 Ratings

Arthur W. Blackstock Jr, M.D.

Chair,
Program Director,
Professor,




Clinical Specialties

Lung Cancer, Pancreatic Cancer

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-3600
Department: 336-713-3600

Email: ablackst@wakehealth.edu

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.A., Wake Forest University , 1985
  • M.D., University of North Carolina-Chapel Hill , 1989
  • Internship, Pitt County Mem Hosp, 1990
  • Internship, Univ No Carolina Affil Hosps, 1994
  • Fellowship, North Carolina Baptist Hospita, 1994

NPI Number

  • 1356323307
Arthur W. Blackstock Jr, M.D.

Doctor Rating

4.7 out of 5

54 Ratings

Arthur W. Blackstock Jr, M.D.

Chair, Radiation Oncology
Program Director, Comprehensive Cancer Center
Professor, Radiation Oncology
Comprehensive Cancer Center
Brain Tumor Center of Excellence
Maya Angelou Center for Health Equity
Cancer Biology

Research Interests

cancer/oncogenesis, vaccines

Contact Information

Academic: 336-713-3600 | Department: 336-713-3600

Email: ablackst@wakehealth.edu

Media Medical Expert »

Recent Publications

Hong TS, Petz JL, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Goodman KA, Jabbour SK, Jones WE III, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Zook J, Suh WW. ACR appropriateness criteria-anal cancer. Gastrointest Cancer Res. 2014;7(1):4-14.

Kilburn JM, Lester SC, Lucas JT Jr, Soike MH, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. J Thorac Oncol. 2014;9(4):572-576.

Kilburn JM, Kuremsky JG, Blackstock AW, Munley MT, Kearns WT, Hinson WH, Lovato JF, Miller AA, Petty WJ, Urbanic JJ. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol. 2014;110(3):505-510.

Lucas JT Jr, Kuremsky JG, Soike M, Hinson WW, Kearns WT, Hampton CJ, Blackstock AW, Urbanic J. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC). Lung Cancer. 2014;85(1):59-65.

Almeida C, Nagarajan D, Tian J, Leal SW, Wheeler K, Munley M, Blackstock W, Zhao W. The role of alveolar epithelium in radiation-induced lung injury. PLoS One. 2013;8(1):e53628.


Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BH. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma. Am J Clin Oncol. 2013;36(3):250-253.

Ayala-Peacock DN, Blackstock AW, Kearns WT, Hinson WH, Munley MT, Miller AA, Petty WJ, Urbanic JJ. Stereotactic body radiation therapy (SBRT) and image guided accelerated hypofractionated radiation therapy (IGAHRT) for the treatment of oligometastatic cancers [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S567-S568.

Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock D, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Urbanic JJ. Is a clinical target volume (CTV) necessary in treatment of thoracic malignancies treated in the modern era combining 4-D imaging and image guided radiation therapy (IGRT)? [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S549.

Kilburn JM, Lester SC, Lucas JT, Blackstock AW, Kearns WT, Hinson WH, Munley MT, Miller AA, Petty WJ, Urbanic JJ. Multiple courses of thoracic radiation therapy (XRT) using stereotactic body radiation therapy (SBRT) as the first or second course of treatment for tumors outside the original high-dose region [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S36.

Lester SC, Kilburn JM, Lucas JT, Munley MT, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Urbanic JJ. Salvage radiation for mediastinal relapse after treatment with accelerated hypofractionated radiation therapy (AHRT) or stereotactic body radiation therapy (SBRT) for stage I/II NSCLC [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S543-S544.

Russo S, Blackstock AW Jr. The 'watch-and-wait' approach for rectal cancer: are outcomes improved with more limited T stage and routine use of MRI for staging? [comment]. Oncology (Williston Park). 2013;27(10):976-977.

Soike M, Kilburn JM, Lucas JT, Ayala-Peacock D, Blackstock AW, Kearns WT, Hinson WH, Miller AT [sic] [Miller AA], Petty WJ, Urbanic JJ. Image guided radiation therapy results in mproved local control in lung cancer patients treated with fractionated radiation therapy for stage IIB-IIIB disease [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S547-S548.

Ayala-Peacock DN, Onyeuku N, Thomas AJ, Garg P, Blackstock AW. A pilot 11C-choline PET/CT imaging study investigating the ability to detect occult metastatic osseous disease in newly diagnosed high-risk prostate adenocarcinoma. Pract Radiat Oncol. 2013;3(2 Suppl 1):S27.

Ayala-Peacock DN, Thomas AJ, Smith H, Garg P, Blackstock AW. A pilot 11C-choline PET-CT imaging study in patients with locally advanced esophageal cancer. Pract Radiat Oncol. 2013;3(2 Suppl 1):S23.

Weaver KE, Danhauer SC, Tooze JA, Blackstock AW, Spangler J, Thomas L, Sutfin EL. Smoking cessation counseling beliefs and behaviors of outpatient oncology providers. Oncologist. 2012;17(3):455-462.

Kimple RJ, Russo S, Monjazeb A, Blackstock AW. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Rev Anticancer Ther. 2012;12(4):469-480.

Jones WE III, Thomas CR Jr, Herman JM, Abdel-Wahab M, Azad N, Blackstock W, Das P, Goodman KA, Hong TS, Jabbour SK, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, Zook J, Suh WW. ACR Appropriateness Criteria: resectable rectal cancer. Radiat Oncol. 2012;7():161.

Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol. 2012;30(32):3953-3959.

Blackstock A, Lally B, Isom S, Paskett E. Impact of marital status and race on survival for patients with colon cancer: an analysis of data from the Surveillance, Epidemiology, and End-Results (SEER) Program [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S539.

Kilburn JM, Kuremsky JG, Blackstock AW, Kearns WT, Hampton CJ, Hinson WH, Miller AA, Petty WJ, Urbanic JJ. Thoracic reirradiation in patients with stereotactic body radiation therapy (SBRT) as first or second course of treatment [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S604.

Kuremsky JG, Petty WJ, Miller A, Hinson WH, Hampton CJ, Blackstock AW, Urbanic JJ. Hypofractionated radiation therapy for stage I and II non-small cell lung cancer [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S153-S154.

Urbanic JJ, Soike M, Hampton CJ, Lucas J, Hinson W, Kearns W, Blackstock AW. Long-term follow-up and patterns of failure for patients with medically inoperable stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S609.

Kilburn KM, Kuremsky JG, Blackstock AW, Kearns WT, Hampton CJ, Hinson WH, Miller AA, Petty WJ, Urbanic JJ. Thoracic re-irradiation in patients with stereotactic body radiotherapy (SBRT) as first or second course of treatment [abstract]. J Thorac Oncol. 2012;7(9 Suppl 4):S253-S254.

Kuremsky JG, Petty WJ, Miller A, HInson WH, Hampton CJ, Blackstock AW, Urbanic JJ. Hypofractionated radiotherapy for stage I and II non-small cell lung cancer [abstract]. J Thorac Oncol. 2012;7(9 Suppl 4):S230.

Lucas JT, Kuremsky JG, Soike M, Hinson W, Kearns WT, Hampton CJ, Blackstock AW, Urbanic JJ. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for stage 1 & 2 non-small cell lung cancer (NSCLC) [abstract]. J Thorac Oncol. 2012;7(9 Suppl 4):S228.

Urbanic JJ, Soike M, Hampton CJ, Lucas J, Hinson W, Kearns W, Blackstock AW. Long-term follow-up and patterns of failure for patients with medically inoperable Stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT) [abstract]. J Thorac Oncol. 2012;7(9 suppl 4):S288.


Stinchcombe T, Socinski MA, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Morris DE. Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2011;29(Suppl):abstr 7016.

Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : Cancer and Leukemia Group B (CALGB) 80003. Cancer. 2011;117(12):2620-2628.

Yang X, Walton W, Cook DN, Hua X, Tilley S, Haskell CA, Horuk R, Blackstock AW, Kirby SL. The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45(1):127-135.

Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011;103(20):1498-1506.

Attia A, Vern-Gross T, Garg PK, Garg S, Thomas A, Smith H, Monjazeb A, Blackstock AW. The utility of 11C-choline positron emission tomography computerized tomography (PET-CT) for staging locally advanced esophageal cancer [abstract]. Int J Radiat Oncol Biol Phys. 2011;81(2 Suppl):S314.

Salama JK, Stinchcombe TE, Gu L, Wang X, Morano K, Bogart JA, Crawford JC, Socinski MA, Blackstock AW, Vokes EE. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 GY) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy:. Int J Radiat Oncol Biol Phys. 2011;81(4):e269-e274.

Center B, Petty WJ, Ayala D, Hinson WH, Lovato J, Capellari J [sic] [Cappellari J], Oaks T, Miller AA, Blackstock AW. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol. 2010;5(1):69-74.

Bogart JA, Hodgson L, Seagren SL, Blackstock AW, Wang X, Lenox R, Turrisi AT III, Reilly J, Gajra A, Vokes EE, et al. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol. 2010;28(2):202-206.

Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW. Outcomes of patients with esophageal cancer staged with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?. J Clin Oncol. 2010;28(31):4714-4721.

Monjazeb AM, Riedlinger G, Isom S, Aklilu M, Geisinger KR, Mishra G, Levine EA, Blackstock AW. Radiotherapy for esophageal cancer: does dose affect outcomes? [abstract]. Int J Radiat Oncol Biol Phys. 2010;78(3 Suppl):S307.

Lally BE, Geiger AM, Urbanic JJ, Butler JM, Wentworth S, Perry MC, Wilson LD, Horton JK, Detterbeck FC, Miller AA, Blackstock AW, et al. Trends in the outcomes for patients with limited stage small cell lung cancer: an analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer. 2009;64(2):226-231.

Blackstock AW, Aklilu M, Lovato J, Degrass L, Sommer J, Howerton R, Mishra G, Levine E, McQuellon R. Aprepitant/5HT-3 antagonist (EMEND) for the prevention of chemoradiation-induced nausea and vomiting (CRINV) in patients receiving gemcitabine/5-FU-based chemoradiation and concurrent upper abdominal radiation for pancreatic cancer [abstract]. J Clin Oncol. 2009;27(Suppl):e20661.

Lally BE, Urbanic JJ, Blackstock AW. Could it be that less is more? [editorial]. Lancet Oncol. 2009;10(5):435-437.

Kim C, Monjazeb AM, Suntharalingam M, Giesinger KR [sic] [Geisinger KR], Blackstock AW. Preoperative versus postoperative chemoradiotherapy in the trimodality management of esophageal cancer. Clin Adv Hematol Oncol. 2009;7(5):327-333.

Urbanic JJ, Lally B, Blackstock AW. 'The best-laid plans ... often go awry ... ' [editorial]. J Thorac Oncol. 2009;4(7):783-784.

Ayala DN, Russo SM, Blackstock AW. Multidisciplinary treatment of resectable rectal cancer. Expert Rev Gastroenterol Hepatol. 2009;3(4):383-394.

Socinski MA, Stinchcombe TE, Halle JS, Moore DT, Petty WJ, Blackstock AW, Gettinger SN, Decker RH, Khandani AH, Morris DE. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC) [abstract]. J Thorac Oncol. 2009;4(9 Suppl 1):S372-S373.

Tepper JE, Blackstock AW. Randomized trials and technology assessment [editorial]. Ann Intern Med. 2009;151(8):583-584.

Socinski MA, Stinchcombe TE, Halle JS, Moore DT, Petty WJ, Blackstock AW, Gettinger SN, Decker RH, Khandani AH, Morris DE. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2009;27(15 Suppl):7528.

Suh WW, Blackstock AW, Herman J, Konski AA, Mohiuddin M, Poggi MM, Regine WF, Cosman BC, Saltz L, Johnstone PAS. ACR appropriateness criteria on resectable rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70(5):1427-1430.

Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Sleeper A, Miller AA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008;26(15):2457-2463.

Hampton CJ, Kearns WT, Urbanic JJ, McMullen KP, Blackstock AW, Hinson WH. Impact of individualized target volumes on stereotactic body radiotherapy treatment planning (SBRT): volumetric analysis [abstract]. Int J Radiat Oncol Biol Phys. 2008;72(1 Suppl):S617.

Hampton CJ, Kearns WT, Urbanic JJ, McMullen KP, Blackstock AW, Hinson WH. Impact of individualized target volumes on stereotactic body radiotherapy treatment planning (SBRT): dosimetric analysis [abstract]. Int J Radiat Oncol Biol Phys. 2008;72(1 Suppl):S625-S626.

Kearns WT, Urbanic JJ, Hampton CJ, McMullen KP, Blackstock AW, Stieber VW, Hinson WH. Radiation safety issues with positron-emission/computed tomography simulation for stereotactic body radiation therapy. J Appl Clin Med Phys. 2008;9(3):141-146.

Lally BE, Blackstock A, Buyyounouski MK, Feigenberg SJ, Scott WJ, Thomas CR, Konski AA. The effect of race on combining surgery and radiation in locally advanced non-small cell lung cancer [abstract]. Int J Radiat Oncol Biol Phys. 2008;72(1 Suppl):S42.

Urbanic JJ, McMullen KP, Stieber VW, Hinson WH, Kearns WT, Hampton CJ, Lovato JF, Livengood K, Rosdahl R, Blackstock AW. A phase I/II dose-escalation/efficacy study, of single fraction stereotactic body radiotherapy (SF-SBRT) for metastatic cancer [abstract]. Int J Radiat Oncol Biol Phys. 2008;72(1 Suppl):S140.

Ayala D, Blackstock AW. Effective treatment strategies for cholangiocarcinoma: the challenge remains [editorial]. Gastrointest Cancer Res. 2008;2(5):251-252.

Socinski MA, Morris DE, Stinchcombe TE, Halle JS, Moore DT, Tynan MT, Siegel MA, Petty WJ, Blackstock AW, Khandani AH, et al. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2008;26(15 Suppl):401s.

Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. Mayo Clin Proc. 2007;82(1):114-129.

Blackstock AW. Cancer of the esophagus In: Gunderson LL, Tepper JE, eds. Clinical radiation oncology. 2nd ed. Philadelphia: Elsevier Churchill Livingstone;2007: 951-972.

Petty WJ, Knight SN, Mosley L, Lovato J, Capellari J, Tucker R, Blackstock AW, Miller MS, Miller AA. A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer. J Thorac Oncol. 2007;2(3):197-202.

Easler J, Fennimore B, Farmer M, Yacoub J, Geisinger K, Aklilu M, Blackstock W, Case D, Levine E, Mishra G. Molecular profiling with MIB-1 correlates with microscopic evidence of residual disease in patients undergoing neoadjuvant therapy for esophageal cancer (EC) [abstract]. Gastroenterology. 2007;132(4 Suppl 2):A854.

Blackstock A, Petty J, Oaks T, Porosnicu M, Clark H, Lovato J, Miller A. Gefitinig (ZD-1839) with concurrent docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel/gefitinib for patients with stage III NSCLC: a phase I study [abstract]. J Clin Oncol. 2007;25(18 Suppl):Abstr18165.

Hinson WH, Kearns WT, Hampton CJ, Urbanic JJ, Blackstock AW, McMullen KP, Stieber VW. SBRT simulations using PET/CT: radiation safety concerns [abstract]. Med Phys. 2007;34(6):2488.

Lally BE, Detterbeck FC, Geiger AM, Thomas CR Jr, Machtay M, Miller AA, Oaks TE, Petty WJ, Robbins ME, Blackstock AW, et al. The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):911-917.

Blackstock AW, Govindan R. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol. 2007;25(26):4146-4152.

Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years?. Oncologist. 2007;12(9):1096-1104.

Russo S, Butler J, Ove R, Blackstock AW. Locally advanced pancreatic cancer: a review. Semin Oncol. 2007;34(4):327-334.

Blackstock AW, Jensen CA, Petty WJ, Oaks T, Porosnicu M, Clark H, Lovato JF, Miller A. Gefitinib (ZD-1839) with concurrent docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel/gefitinib for patients with stage III NSCLC: a phase I study [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S476.

Kim C, Farmer MR, Yacoub J, Monjazeb A, Levine EA, Aklilu M, Geinsinger [sic] KR [Geisinger KR], Mishra G, Melin S, Blackstock AW. Tri-modality therapy for esophageal cancer: mucinous histology is associated with decreased pathologic response rates to neoadjuvant chemoradiation therapy [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S267.

Lally BE, Shaw EG, Knisely JPS, Blackstock AW, Robbins MC, Geiger AM. Low grade gliomas: demographic, tumor and treatment factors associated with survival [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S185.

Monjazeb AM, Farmer MR, Mattern M, Mebea A, Levine EA, Geisinger KR, Mishra G, Melin S, Blackstock AW. Patterns of failure for esophageal cancer patients optimally staged with 18-F-FDG-PET and observed after chemo-radiotherapy [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S274.

McMullen KP, Matthews C, Blackstock AW. Rectal cancer: adjuvant therapy and new directions. Rev Recent Clin Trials. 2007;2(1):27-32.

Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer. 2006;95(3):260-265.

Blackstock AW, Socinski MA, Bogart J, Gu L, Wang X, Green M, Vokes EE. Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): preliminary report of Cancer and Leukemia Group B (CALGB) 30105 [abstract]. J Clin Oncol. 2006;24(18 Suppl Pt I):374s.

Blackstock AW, Aklilu M, Lovato J, Farmer MR, Mishra G, Melin SA, Oaks T, Geisinger K, Levine EA. Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer. Int J Gastrointest Cancer. 2006;37(1):7-14.

Butler JM, Lally BE, D'Agostino R, Urbanic JJ, Wentworth S, Paskett E, Blackstock AW. Impact of race and marital status on survival and stage at presentation for patients with colorectal cancer: an analysis of data from the Surveillance, Epidemiology, and End-Results (SEER) program [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S70.

Farmer MR, Yacoub J, Aklilu M, Levine EA, Geisinger K, Mishra G, Melin S, Blackstock AW. Tri-modality therapy for esophageal cancer: hemoglobin levels are prognostic for survival but do not predict response to radiochemotherapy [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S269.

Lally BE, Urbanic JJ, Butler JM, Wentworth S, Thomas CR, Blackstock A. Outcomes of patients with limited-stage small cell lung cancer treated with radiotherapy: analysis of data from the Surveillance, Epidemiology, and End-Results (SEER) program [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S87.

Urbanic JJ, Hinson WH, Stieber VW, Butler JM, Kearns WT, Hampton CJ, Blackstock AW. Heterogeneity corrections in stereotactic body radiotherapy (54 Gy in 3 fractions) for lung tumors significantly alter delivered dose [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S479-S480.

Wentworth S, Lally B, Butler J, Urbanic J, Blackstock A. Impact of race on survival and radiotherapy use in patients with non-metastatic rectal cancer: analysis of data from the Surveillance, Epidemiology and End-Results (SEER) program [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S68.

Lally BE, Butler J, Mishra G, Paskett ED, Blackstock AW. The impact of ethnicity on survival for patients with pancreatic cancer: a SEER analysis [abstract]. In: 2006 Gastrointestinal Cancers Symposium Abstracts; 2006 Jan 26-28; San Fransciso (CA). 2006;():Abstr 100.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Radiation Oncology

Clinical Specialties

Lung Cancer, Pancreatic Cancer
Arthur W. Blackstock Jr, M.D.

Arthur W. Blackstock Jr, M.D.

Chair, Radiation Oncology
Program Director, Comprehensive Cancer Center
Professor, Radiation Oncology
Comprehensive Cancer Center
Brain Tumor Center of Excellence
Maya Angelou Center for Health Equity
Cancer Biology

Doctor Rating

4.7 out of 5

Arthur W. Blackstock Jr, M.D.54 Ratings

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.7
CP efforts to include in decisions
4.7
CP explanations of prob/condition
4.7
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.8
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.8
Time CP spent with patient
4.7
Wait time at clinic
3.9

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.